CancerNCT07860801
Study of Vaping Use Among Adolescent and Young Adult Patients With Cancer
An observational study of Cancer and Vaping, run by Memorial Sloan Kettering Cancer Center at 7 sites in United States.
Trial summary
The purpose of this study is to learn more about how adolescent and young adult (AYA) cancer patients, their parents and caregivers (referred to as a carebuddy in this study), and their healthcare providers think about and communicate around vaping and tobacco use. Read more about this study
- Who is it for?
- Ages 15 years and olderHealthy volunteers can take part
- What is being tested?
- Study assessments
- How many people
- 80 participants
- Where
- 7 sitesUnited States
- Study dates
- 30 Sep 2026to 30 Sep 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: MSK clinics
Who may be able to join
- History of cancer diagnosis;
- Report vaping within the past 12 months as documented in the medical record, clinician note, and/or self-report;
- Age 15-39 years at date of consent;
- Receiving or have received treatment at MSK;
- Iidentify English as primary language as per medical record
- Inclusion criteria for Parents/Carebuddy (i.e., family member, friend):
Show all 9Show fewer
- Self-report they are the parent/carebuddy of an AYA patient who currently or previously vaped.
- Conducts ≥2 AYA clinical consultations weekly as per self-report or EMR;
- Is an MSK clinician (i.e., nurse practitioner, social worker, physician assistant, physician)
Who cannot join
- Acute psychiatric symptoms impairing participation as per the EMR or as per clinician judgment;
- Reports exclusive use of combustible or smokeless tobacco products (i.e., no history of nicotine vaping).
Trial locations and contacts
7 sites in 1 country. Contact the study team or a site near you to ask about taking part.
7 sites in 1 country
United States7 sites
Memorial Sloan Kettering at Basking Ridge (Consent Only)
Basking Ridge, New Jersey, 07920
Memorial Sloan Kettering Suffolk- Commack (Consent Only)
Commack, New York, 11725
Memorial Sloan Kettering Westchester (Consent Only)
Harrison, New York, 10604
Memorial Sloan Kettering Monmouth (Consent only)
Middletown, New Jersey, 07748
Memorial Sloan Kettering Bergen (Consent Only)
Montvale, New Jersey, 07645
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
New York, New York, 10065
Memorial Sloan Kettering Nassau (Consent Only)
Uniondale, New York, 11553
About this study
Official title: CLEAR-AYA: Moving Beyond the Clouds - Pilot Study of Vaping Use Among AYA Patients With Cancer
The purpose of this study is to learn more about how adolescent and young adult (AYA) cancer patients, their parents and caregivers (referred to as a carebuddy in this study), and their healthcare providers think about and communicate around vaping and tobacco use. The researchers hope this information will help them develop educational materials and provider training tools that are appropriate for young people with cancer.
A Community Advisory Board that is made up of AYA patients, parents/caregivers, and healthcare providers, is helping to guide the study. The board will review the materials, give feedback, help the study team understand the findings, and provides input to make sure the study is appropriate and practical for participants.
- Being tested
- Study assessments
- Keywords
- Vaping, Tobacco Treatment Program, 26-337, Focus groups, Surveys
- Medical subject headings
- Neoplasms, Vaping
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Study assessmentsOther
Patient and Parent/Carebuddy Survey, Provider Survey, AYA Patient Focus Group Guide, Parent/Caregiver Focus Group Guide. AYA patient and parent/carebuddies participants will participate in virtual focus group sessions conducted via Zoom or Microsoft Teams. Focus groups will utilize structured discussion guides informed by talk-aloud (think-aloud) methodology. The research staff will maintain communication with participants before their focus groups via call, email, text and/or MyChart before their focus groups to remind them about their upcoming focus group as well as to have their computers charged.
| Study group | Role | What they receive |
|---|---|---|
| Adolescent / Young Adult (AYA) who have or had cancer | Not described Receives: Other: Study assessments | |
| Carebuddy of an Adolescent / Young Adult (AYA) | Not described Receives: Other: Study assessments | |
| Healthcare providers of Adolescent / Young Adult (AYA) | Not described Receives: Other: Study assessments |
What is being measured
The primary outcome is the main question the study is designed to answer.
support needs to inform the development of developmentally appropriate vaping cessation resources.
using study assessments Survey measures will include: 1) Sociodemographic and medical characteristics (e.g., age, race/ethnicity, education, employment status/role); 2) vaping use and knowledge, including frequency of use, product type, and related perceptions; and 3) for providers only, current communication practices related to vaping use among AYA patients, perceived barriers, educational needs, and suggested adaptations to provider communication training materials.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Oct 2026
- Study start30 Sep 2026
- Primary completion30 Sep 2027 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Gleneara Bates-Pappas, PhD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07860801
- Sponsor's protocol ID
- 26-337
- Status last verified
- Oct 2026
- First submitted
- 30 Sep 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CLEAR-AYA: Moving Beyond the Clouds - Pilot Study of Vaping Use Among AYA Patients With Cancer
- ClinicalTrials.gov ID
- NCT07860801
- Acronym / sponsor ID
- 26-337
- Keywords
- Vaping, Tobacco Treatment Program, 26-337, Focus groups, Surveys
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterUniversity, hospital or other
- Study start
- 30 Sep 2026 (actual)
- Primary completion
- 30 Sep 2027 (estimated)
- Study completion
- 30 Sep 2027 (estimated)
- First posted
- 6 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to learn more about how adolescent and young adult (AYA) cancer patients, their parents and caregivers (referred to as a carebuddy in this study), and their healthcare providers think about and communicate around vaping and tobacco use. The researchers hope this information will help them develop educational materials and provider training tools that are appropriate for young people with cancer.
A Community Advisory Board that is made up of AYA patients, parents/caregivers, and healthcare providers, is helping to guide the study. The board will review the materials, give feedback, help the study team understand the findings, and provides input to make sure the study is appropriate and practical for participants.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Adolescent / Young Adult (AYA) who have or had cancer | – | Other: Study assessments |
| Carebuddy of an Adolescent / Young Adult (AYA) | – | Other: Study assessments |
| Healthcare providers of Adolescent / Young Adult (AYA) | – | Other: Study assessments |
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- MSK clinics
Key inclusion criteria (9 listed)
- History of cancer diagnosis;
- Report vaping within the past 12 months as documented in the medical record, clinician note, and/or self-report;
- Age 15-39 years at date of consent;
- Receiving or have received treatment at MSK;
- Iidentify English as primary language as per medical record
Key exclusion criteria (2 listed)
- Acute psychiatric symptoms impairing participation as per the EMR or as per clinician judgment;
- Reports exclusive use of combustible or smokeless tobacco products (i.e., no history of nicotine vaping).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Study assessmentsPatient and Parent/Carebuddy Survey, Provider Survey, AYA Patient Focus Group Guide, Parent/Caregiver Focus Group Guide. AYA patient and parent/carebuddies participants will participate in virtual focus group sessions conducted via Zoom or Microsoft Teams. Focus groups will utilize structured discussion guides informed by talk-aloud (think-aloud) methodology. The research staff will maintain communication with participants before their focus groups via call, email, text and/or MyChart before their focus groups to remind them about their upcoming focus group as well as to have their computers charged. | Other | Adolescent / Young Adult (AYA) who have or had cancer, Carebuddy of an Adolescent / Young Adult (AYA), Healthcare providers of Adolescent / Young Adult (AYA) |
Primary outcome
support needs to inform the development of developmentally appropriate vaping cessation resources.
Time frame: 1 year
using study assessments Survey measures will include: 1) Sociodemographic and medical characteristics (e.g., age, race/ethnicity, education, employment status/role); 2) vaping use and knowledge, including frequency of use, product type, and related perceptions; and 3) for providers only, current communication practices related to vaping use among AYA patients, perceived barriers, educational needs, and suggested adaptations to provider communication training materials.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Gleneara Bates-Pappas, PhD principal investigator
Memorial Sloan Kettering Cancer Center
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer and Vaping, run by Memorial Sloan Kettering Cancer Center at 7 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
support needs to inform the development of developmentally appropriate vaping cessation resources. (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.